Country: দক্ষিণ আফ্রিকা
ভাষা: ইংরেজি
সূত্র: South African Health Products Regulatory Authority (SAHPRA)
Janssen
PREPULSID® 30 mg suppositories SCHEDULING STATUS: Schedule 4. PROPRIETARY NAME (and dosage form): PREPULSID ® 30 mg suppositories COMPOSITION: Each suppository contains 31,16 mg cisapride monohydrate equivalent to 30 mg cisapride anhydrous. PHARMACOLOGICAL CLASSIFICATION: A.11 Medicines acting on the gastro-intestinal tract. PHARMACOLOGICAL ACTION: IN ANIMALS In isolated organs PREPULSID prevents gastric atony and enhances gastric peristaltic activity, antroduodenal co- ordination and small and large bowel motility. In dogs PREPULSID enhances digestive antroduodenal motility and co- ordination, accelerates gastric emptying, increases small bowel propulsive contractions and shortens intestinal transit time. Gastric secretion is not affected. The mechanism of action of PREPULSID is mainly due to an enhancement of the physiological release of acetylcholine at the myenteric plexus level. PREPULSID does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity. In vitro studies have shown that cisapride has serotonin (5-HT 4 ) receptor agonist activity in the colon. IN MAN GASTROINTESTINAL MOTILITY: Oesophagus PREPULSID increases oesophageal peristaltic activity and lower oesophageal sphincter tone. PREPULSID decreases oesophageal reflux of gastric contents and improves oesophageal clearance. Stomach PREPULSID increases gastric and duodenal contractility and introduodenal co-ordination. PREPULSID decreases duodenagastric reflux. PREPULSID accelerates gastric and duodenal emptying. Intestinal region PREPULSID enhances intestinal propulsive activity and accelerates small and large bowel transit. OTHER EFFECTS: Due to its lack of direct cholinomimetic effects, PREPULSID does not increase basal and pentagastrin induced gastric acid secretion. Due to its relative lack of সম্পূর্ণ নথি পড়ুন